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Executive summary 
The objective of the present paper is to document the burden of disease and associated costs due to 
respiratory syncytial virus (RSV) and perceived use of a future pediatric prophylactic vaccine for RSV in 
Kenya in order to inform local decision-makers as well as to evaluate whether the context is favorable for 
RSV vaccine trials to protect young children in Kenya.  
A brief literature review was done in order to identify gaps in available data of the epidemiology of RSV 
in developing countries. The burden and costs associated with RSV in Kenya were estimated. The state of 
pediatric prophylactic vaccine development was reviewed. Finally, perceptions of key stakeholders at the 
international and national levels regarding feasibility and desirability of an RSV vaccine were also 
documented. 
There remain information gaps regarding RSV associated burden, particularly in developing countries 
where the vast majority of severe cases and deaths occur. There are insufficient long term studies and few 
studies that look at within country variation geographically and factors relating to this. More information 
is needed on the incidence of RSV in young children as current estimates vary considerably between 
studies. Post-mortem assessment of children dying of respiratory infections should be considered as the 
mortality due to RSV is poorly defined and in all likelihood underestimated. Potential long term sequelae 
of RSV must be verified. Data on costs associated with the disease are limited.  
In Kenya, RSV was estimated to be the cause of a substantial disease burden in young children resulting 
annually in 77,539 cases of lower respiratory tract infection (LRTI), 49,207 cases of severe LRTI, 37,278 
outpatients visits and 9,311 hospitalizations among infants, as well as 10,162 hospitalizations and 2,376 
deaths in children aged 0-4 years old. Although causing 47% less mortality than rotavirus, RSV results in 
16% more hospitalizations than rotavirus. The total cost in health care attributable to RSV among children 
less than 5 years old for the Kenyan government in 2009 was US$ 3 million (252,398,234 KSh); while 
the societal cost represents an additional US$ 2 million (175,582,763 KSh). These costs represent close to 
half of the costs associated to rotavirus. However, they do not take into consideration costs for episodes 
occurring in the community and loss of productivity from the caretakers when they do not seek formal 
medical advice. 
Vaccines appear like a most promising means of control and current progress in the research for an RSV 
prophylactic vaccine to protect young children provides hope that such a vaccine can be developed. There 
is consensus among national and international stakeholders that after rotavirus and malaria, RSV vaccine 
should be the next to be made available. Most stakeholders were favorable of a RSV vaccine trial in 
Kenya on the basis that it would be beneficial to have local data for an eventual larger campaign.  
Interest in RSV and a preventive vaccine for young children from local authorities was however low. 
Underlying this could be the numerous competing health priorities, the absence of a vaccine candidate 
and the lack of knowledge of the RSV burden. An information campaign might be beneficial to foster a 
more informed opinion regarding a vaccine trial. It is hoped that the data gathered in this study can serve 
that purpose and in the assessment of an eventual vaccine candidate.  
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Introduction 
 
The objectives of the present paper are to document the burden associated with respiratory 
syncytial virus (RSV) globally and more specifically in Kenya, as well as the current 
developments of pediatric prophylactic vaccine for the disease and the opinions of key 
stakeholders at the international and national levels regarding feasibility and desirability of an 
RSV vaccine.  
The first section discusses the virus in general and the evidence documenting the burden 
attributable to RSV in all age groups, but particularly in developing countries. It will further 
enable identification of data gaps on RSV epidemiology and disease burden. The subsequent 
sections concentrate on RSV in children. The second section attempts to evaluate the health, 
social and economical consequences of RSV in children in the Kenyan context. The third section 
describes the vaccines to protect young children currently under development and their state of 
advancement. The fourth section reviews the perceptions of the experts in the field of RSV and 
immunization. Finally, conclusions are presented accompanied by recommendations for actions 
including research needs. Contacts of experts contacted, methods of literature reviews as well as 
burden and cost estimates are presented in appendix. 
The elements presented in the following pages will inform decision-makers in Kenya about the 
burden associated with RSV in the country and will contribute to determining whether the 
context is favorable for the trial of a RSV vaccine to protect young children in Kenya. 
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Respiratory Syncytial Virus and Global Burden 
 
Respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus of to the genus 
Pneumovirus within the subfamily Pneumovirinae and the family Paramyxoviridae.  There are 
two subtypes of RSV, A and B, differentiated primarily on the variability of the G gene and 
encoded protein. RSV produces large, usually annual, epidemics (P. Collins, Chanock, & 
McIntosh, 1996).   
RSV is the single most important etiological agent causing respiratory disease in infancy 
(Pediatrics, 2009). It is the leading cause of severe lower respiratory tract infections (LRTI) in 
infants and young children, in particular causing pneumonia and bronchiolitis (Hall, 2001). It is 
the principal cause of pneumonia after the bacteria Streptococcus pneumoniae and Haemophilus 
influenza, and consequently RSV is the main viral cause of pneumonia (Berkley et al., 2010).  
Primary RSV infection usually occurs early in life (Glezen, Taber, Frank, & Kasel, 1986).  Two 
thirds of infants are infected with RSV during their first year and infection is usually universal by 
the age of two (P. Collins et al., 1996). The peak of hospitalization for RSV is between the ages 
of 2 and 4 months (P. Collins & Murphy, 2006), which coincides with diminishing titer of 
maternally derived antibodies (P. Collins et al., 1996).  Repeated infections are common due to 
incomplete immunity and are correlated with lower levels of serum neutralizing antibodies 
(Glezen et al., 1986). However, respiratory tract symptoms are more severe with primary 
infection than in subsequent infections and more severe in young infants than in older children 
(Henderson, Collier, Clyde Jr, & Denny, 1979). Most infections are symptomatic (C. Hall et al., 
1976). RSV-infected infants almost universally experience upper respiratory tract symptoms, and 
20% to 30% develop lower respiratory tract disease with their first infection (Pediatrics, 2009). 
In older children and adults, RSV infection usually manifests as upper respiratory tract illness 
(Pediatrics, 2009). 
The incubation of RSV is 4-5 days (P. Collins et al., 1996). In newborns, infants and young 
children RSV causes upper and lower respiratory tract disease characterized by fever, coryza, 
cough, expiratory wheezing and respiratory distress (Schickli, Dubovsky, & Tang, 2009). The 
symptoms last between 7 to 12 days (P. Collins et al., 1996). It is not clear from the literature 
whether strain A causes more severe disease than B.  A community study of Kenyan children 
found a median duration of shedding of 4 days (Okiro et al., 2010). Shedding lasts longer in 
more severe hospitalized cases and in infancy, presumably associated with primary infections 
(Okiro et al., 2010). Children with a history of RSV infection have a shorter duration of 
shedding. Although most re-infections occurred in separate epidemics, 23% of re-infections 
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occurred during the same epidemic (Nokes et al., 2008). Ohuma et al. suggest partial protection 
to re-infection of 60-70% for up to 6 months following infection (Ohuma et al., n.d.).    
Up to 40% of infants experience symptoms of bronchiolitis or pneumonia during their first 
episode of RSV infection (Holberg et al., 1991). RSV bronchiolitis is the leading cause of infant 
hospitalization in industrialized countries (C. Hall, 2001). During their first RSV infection, 
between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or 
pneumonia and 0.5% to 2% require hospitalization (Pediatrics, 2009). In Canada, it was 
estimated that approximately 75% of hospitalizations for RSV disease occur in infants and 
children who were previously healthy (P. Collins et al., 1996) .  Among children aged less than 
five years of age, RSV is associated with 20% of hospitalizations, 18% of emergency department 
visits and 15% of office visits during the winter respiratory viral season in US (C. B. Hall et al., 
2009). It is believed an acute episode of RSV may cause long term sequelae such as further 
episodes of wheezing, of pneumonia and asthma. It is not clear whether children affected already 
had predisposing conditions to such respiratory problems or if the acute RSV episode would be 
the real cause. Studies from the United States and Australia suggest that many children who 
develop bronchiolitis and asthma are born with narrow airways that predispose to these problems 
(Hament, Kimpen, Fleer, & Wolfs, 1999; Poulsen, Benn, Roth, Lisse, & Aaby, 2006). A short 
term (3 years) increased risk of pneumonia was observed in Gambian children following severe 
RSV infection (Weber et al., 1999).   
It is not clear whether RSV infection may contribute to secondary bacterial pneumonia. While 
enhanced bacterial adherence has been documented for respiratory cells infected with RSV 
(Hament, Kimpen, Fleer, & Wolfs, 1999), the incidence of concomitant or secondary serious 
bacterial infection in association with RSV infection appears to be quite low (< 1%), except for 
otitis media, which may occur in as many as 40% of cases (R. Welliver & Cherry, 2006). In a 
study from Kenya, in children admitted with pneumonia, bacteremia was significantly less 
common among RSV-positive children than RSV-negative children (Nokes et al., 2009). Otitis 
media is not observed in association with RSV in Kenya.  
In addition to young children, RSV can cause diseases in people of all ages, most severely in the 
elderly and in immune-compromised individuals (Kim et al., 2010). Asthma, cystic fibrosis and 
chronic cardiopulmonary disease may be severely exacerbated by RSV infection (Meissner, 
2003; Thompson et al., 2003). RSV causes higher mortality among elderly than influenza in non-
pandemic years (Falsey et al., 1995).  
 
Data from developing countries are scarce relative to that from industrialized countries. They 
have been summarized by Weber (Weber, Mulholland, & Greenwood, 1998) and Nokes (D. 
Nokes, 2006). Since the last review covering articles published before 2005, five denominator-
based studies in developing countries have been published from urban poor South Africa (Madhi, 
Kuwanda, Cutland, & Klugman, 2006), rural India (Broor et al., 2007), rural Thailand (Fry et al., 
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2010) and rural Kenya (3 studies) (Berkley et al., 2010; Nokes et al., 2008, 2009); see literature 
search strategy Burden in appendix 1). Only two of these involved active surveillance in the 
community which captures more cases than passive hospital surveillance (Broor et al., 2007; 
Nokes et al., 2008).  
Nokes et al. (Nokes et al., 2008) found that only between 20 and 25% of patients presenting to 
outpatient health facilities with RSV-associated severe lower respiratory tract infections (LRTI) 
were hospitalized (RSV-associated hospitalization), while the World Health Organization 
(WHO) guidelines recommend hospital admission for all such cases. While the study may have 
influenced the decision to refer, because the patients were able to return free of charge if the 
child’s condition deteriorated, it still demonstrates that hospital data clearly underestimate the 
burden of severe pneumonia due to RSV. As for RSV burden in adult populations, only the study 
in Thailand evaluated it through passive surveillance (Fry et al., 2010). None of the studies 
estimated the cost associated to RSV.  
Recently, Nair et al. estimated that RSV results in an estimated 33.8 (95% CI 19.3–46.2) million 
new episodes of RSV-associated acute lower respiratory infections (ALRI) worldwide in 
children younger than 5 years (22% of ALRI episodes), with at least 3.4 (2.8–4.3) million 
episodes of severe RSV-associated ALRI necessitating hospital admission in 2005 (Nair et al., 
2010). Although associated with greater uncertainty than for morbidity estimates, it was 
estimated that RSV might be responsible for 53,000 to 199,000 deaths annually in the children 
under 5 years old age group; 99% of which occur in developing countries (Harish Nair et al., 
2010). The burden could however have been underestimated in the past with the use of 
conventional techniques of cell culture or immunofluorescent antibody tests (IFAT) which have, 
individually, lower sensitivity than nucleotide amplification methods. Further, conventional 
serologic testing of acute convalescent serum specimens cannot be relied on to confirm infection 
in young infants in whom sensitivity may be low (Pediatrics, 2009).  Modern molecular methods 
such as reverse transcription polymerase chain reaction (RT-PCR) offer greater sensitivity. In 
some studies, PCR assays have increased RSV detection as much as twofold over viral isolation 
or antigen detection (Pediatrics, 2009). Thus these methods may require re-evaluation of the 
epidemiological portrait for RSV. 
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Kenyan context 
 
There are reports on RSV seasonal patterns from only two areas in Kenya: Nairobi (Hazlett et al., 
1988) and Kilifi (Nokes et al., 2009).  The pattern in Kilifi was quite regular over the last 7 or so 
epidemics. In that region, they started around November or December and finished in April or 
June. The epidemic’s average duration is 18 weeks (range 13–27 weeks) (Nokes et al., 2009). 
More data from elsewhere in the country is awaited to determine variation throughout the 
country. 
There is currently limited information available in Kenya on the epidemiology of RSV, as well 
as burden and costs estimates attributable to RSV infections. 
Estimation of the burden of RSV in Kenya 
Using available data, it was sought to estimate the burden attributable to RSV.  
Methods of estimation 
Incidence rates of RSV associated events and prevalence of RSV may vary according to the case 
definition, methods of sampling, assays, period, area of the study, type of surveillance (active or 
passive), sample size and concurrent illnesses (HIV, malnutrition, etc.). 
RSV associated events may be estimated in terms of the proportion of cases of acute respiratory 
infections (ARI), LRTI or pneumonia in which RSV was identified. ARI includes respiratory 
infections in both the upper and the lower tract, but not infections which are not considered acute 
such as tuberculosis for example. LRTI which is often used as a synonymous for pneumonia, can 
however also apply to other types of infection including lung abscess and acute bronchitis, 
depending on the case definition. Pneumonia is an inflammatory condition of the lungs which 
may have various causes, including RSV. When assessing epidemiological studies, it is 
preferable to refer to case definitions as for example, pneumonia may be defined in numerous 
ways. 
The only RSV incidence rate estimates currently available for Kenya are from the research 
accomplished in Kilifi District (Berkley et al., 2010; Nokes et al., 2008, 2009). They are 
presented in appendix 4. Selected Kilifi District rates were thus used to estimate provincial and 
national incidence of RSV associated events (from references (Nokes et al., 2009; 2008); see 
rates in blue in appendix 6). Provincial data from the Kenya Demographic and Health Survey 
2008-2009 (KDHS) were used to adjust the rates from Kilifi District Hospital to each region 
(Kenya National Bureau of Statistics, 2010). 
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KDHS is a household-based population and health survey, with a sample of 10,000 households 
distributed over the provinces of Kenya.  In the 2008-9 survey a total of 3,973 mothers of 5,481 
children born in the preceding five years were asked for each child if he or she experienced acute 
respiratory infection (ARI)1 in the two weeks preceding the interview and whether they sought 
medical care. The ratio of each province-specific likelihood to the Coast likelihood was 
calculated using this 2-week prevalence of ARI in children under 5 years old from the KDHS 
converted to annual incidence (see method in reference (Division for the Control of Diarrhoea 
and Acute Respiratory Disease, 1994)). The likelihood of ARI alone was used to adjust the LRTI 
and severe LRTI rates while the combined likelihood of ARI and seeking medical care rates was 
used to adjust the rates of hospitalizations and outpatient visits. The crude incidence was then 
calculated applying the obtained rates to Kenya 2009 Population Census data (Government of 
Kenya, 2010).  
 
Such a method of calculating the likelihood ratio assumes that Kilifi district rates apply to the 
whole Coast region and further that the likelihood ratios calculated using KDHS ARI data are 
close to real epidemiology of RSV which cannot be verified in the absence of regional data. 
Further, these likelihood ratios calculated using the 0-4 year-old age group are applied to the 
infants for certain indicators, while the epidemiology of RSV by age group may differ regionally.  
 
Community data on RSV were available for children under the age of 30 months and not for the 
full range of children under 5 years old. Thus, to estimate the total incidence of RSV associated 
events in the children under 5 years old (including the community burden), KDHS 2 week 
prevalence of children under 5 years old with symptoms of ARI for each Province was converted 
into annual incidence using the method presented earlier. It is important to note that in KDHS, 
ARI are defined as cough accompanied by short, rapid breathing, which was chest-related and 
thus might be considered a proxy for pneumonia. The incidences were transformed into 
incidence rates using Kenya 2009 Population Census data (Government of Kenya, 2010).   
 
To estimate the outpatient consultations of children under 5 years old, two different methods 
were used. Another source of information was used namely Kenya Health Information System 
(HIS) (Kenya MoPHS, n.d.). HIS is a national system at the Ministry of Public Health and 
Sanitation (MoPHS) obtaining data for outpatient consultations in all health care institutions by 
districts (Gessner, Shindo, & Briand, 2011). The data was collected in 2010. The pneumonia 
incidences were adjusted for underreporting. The recorded pneumonia outpatient consultations 
from the HIS and the reported pneumonia cases seeking medical advice or care KDHS were each 
multiplied by the proportion of pneumonia associated to RSV (see discussion and table below).  
The RSV associated hospital mortality of children under 5 years old was calculated by 
multiplying the number of children under 5 years old hospitalized with RSV by Kilifi mortality 
                                                          
1 defined as cough accompanied by short, rapid breathing, which was chest-related, considered a proxy for pneumonia. 
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rate among children hospitalized with severe or very severe pneumonia. Finally the total 
mortality, including the community mortality, was obtained by multiplying the KDHS mortality 
rate by the prevalence of pneumonia associated deaths (Ombok et al., 2010) and then by the RSV 
associated pneumonia prevalence. 
Table 1 below summarizes the estimation methods employed for each indicator. 
Table 1:  Methods employed to estimate the incidence of various RSV associated events. 
Indicator  Estimation Methods  
LRTI  <1 year old 
Kilifi rate of RSV associated LRTI from reference (Nokes et al., 
2008)(104/1000 CYO) multiplied by regional likelihood ratios 
(region/Coast) calculated using KDHS data (with symptoms of ARI in the 
preceding 2 weeks; (Kenya National Bureau of Statistics, 2010)). 
Severe LRTI <1 year old 
Kilifi rate of RSV associated severe LRTI from reference reference (Nokes 
et al., 2008) (66/1000 CYO) multiplied by regional likelihood ratios 
(region/Coast) calculated using KDHS data (with symptoms of ARI in the 
preceding 2 weeks). 
Pneumonia <5 years old 
Incidence rate obtained from KDHS 2 week prevalence of children < 5 
years old with symptoms of ARI converted into annual incidence multiplied 
by RSV prevalence (see discussion and table below). 
Outpatient consultations  
<1 year old 
Kilifi rate of RSV associated LRTI from reference (Nokes et al., 2008) 
(50/1000 CYO) multiplied by regional likelihood ratios (region/Coast) 
calculated using KDHS data (seeking medical advice). 
Outpatient consultations 
<5 years old 
Pneumonia incidence from HIS and KDHS multiplied by RSV prevalence 
(see discussion and table below).  
Hospitalizations  
<1 year old 
Kilifi rate of RSV associated LRTI from references (Berkley et al., 2010; 
Nokes et al., 2008) (13-20.4/1000 CYO) multiplied by regional likelihood 
ratios (region/Coast) calculated using KDHS data (seeking medical advice). 
Hospitalizations  
<5 years old 
Kilifi rate of RSV associated LRTI from references (Berkley et al., 2010; 
Nokes et al., 2009)(2.93-5.35/1000 CYO) multiplied by regional likelihood 
ratios (region/Coast) calculated using KDHS data (seeking medical advice). 
Hospital mortality  
<5 years old 
Incidence of hospitalization of children <5 years old multiplied by Kilifi 
mortality rate among children hospitalized with severe or very severe 
pneumonia from reference (Nokes et al., 2009) (0.22 deaths per 1000 
hospitalizations). 
Total mortality <1 year old 
and <5 years old  
Mortality rate from KDHS multiplied by the prevalence of pneumonia 
associated deaths (Ombok et al., 2010) multiplied by the RSV associated 
pneumonia prevalence (see discussion and table below). 
1 extrapolated from hospitalizations which are 26% of all consultations, 13*100/26=50. 
Notes : CYO child-years of observation 
The grey background indicates the same method was employed.  
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RSV prevalence 
 
As mentioned previously, the proportion of respiratory infections associated with RSV may vary 
according to the case definition, methods of sampling, assays, period and area of the study 
among other factors. Table 2 summarizes the most relevant estimates available from the 
literature.  
Table 2: RSV Prevalence Estimates from the Literature 
 
Population RSV Prevalence Period Area 
Collection;  
Assay 
Reference 
< 5 years old hospitalized 
for severe pneumonia 
15.3% (20% 
among infants) 
2002-2007 
Kilifi District Hospital, 
Kenya 
NW or 
NPA; IFAT 
(Nokes et 
al., 2009) 
< 5 years old hospitalized 
for severe ARI 
12% 
1981-1982 
(1 year) 
Kenyatta National 
Hospital, Nairobi, 
Kenya 
NPA & TS; 
IFAT 
(Hazlett et 
al., 1988) 
< 12 years old hospitalized 
for severe pneumonia 
34% 2007 
Kilifi District Hospital, 
Kenya 
NPA; PCR 
(Berkley 
et al., 
2010) 
< 5 years old hospitalized 
for severe pneumonia 
6.2% 
2006-2007 
(one year) 
Manhiça District 
Hospital, Mozambique 
NPA; PCR 
(O’Callag
han-
Gordo et 
al., 2011) 
Children outpatient and/or 
hospitalized for ARI 
2-25% (median 
12%), 
Hospitalized 1-
13%  (median 
appr. 8) 
11 hospital based studies in sub-Saharan Africa 
between 1980 and 2009. Various collection methods 
and assays. 
(Gessner 
et al., 
2011) 
Notes:  
Severe pneumonia includes very severe.  
IFAT Immunofluorescent Antibody Test 
NPA  Nasopharyngeal aspirate 
NW Nasal washing 
PCR Polymerase Chain Reaction 
TS  Throat swab 
 
RSV prevalence monitored over 5 years in children less than 5 years of age hospitalized for 
LRTI was 15.3% (20% among infants) and 27% during epidemics (32% among infants) in Kilifi 
District Hospital screening for antigen using an IFAT (Nokes et al., 2009). In a community study 
in the same area, RSV was identified in 13% of all LRTIs, 19% of severe LRTIs and 5% of 
hospitalizations in children aged less than 30 months (Nokes et al., 2008). In a one year study, 
the prevalence of RSV in children under 12 year-old hospitalized at Kilifi District Hospitals for 
severe pneumonia was 34% using PCR assay (Berkley et al., 2010). In another one year study in 
rural Mozambique, this proportion was 6.2% of the severe pneumonia cases using PCR 
(O’Callaghan-Gordo et al., 2011).  
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Nokes and al. (Nokes et al., 2009) study covers a long period and hence is less subject to chance 
variation than the other reported studies.  However, it is based on IFAT which, though quite 
sensitive, is thought to be less so than PCR.  Nokes et al. RSV prevalence is further supported by 
another study based at Kenyatta National Hospital (Hazlett et al., 1988). The prevalence of RSV 
among children under 5 years old admitted with severe ARI (for which the case definition was 
similar to Nokes et al. severe pneumonia definition) was 12% in that study. Thus a 15.3% RSV 
prevalence among severe pneumonia cases appeared like an appropriate compromise. This 
however assumes the RSV prevalence does not change from one region to another and is the 
same in children no matter the outcome of interest (severe LRTI, hospitalization for severe 
pneumonia, death, etc). Finally, the estimates obtained using these methods and data are 
presented in appendixes 5 and 6. They are discussed below. National estimates are presented in 
Table 3.  
 
Table 3: Key Estimates of RSV Associated Events Incidence in Kenya, 2009 (see estimation 
methods in table 1 above). 
Indicator RSV cases per annum 
RSV incidence  
(cases/ 1000 CYO) 
LRTI <1 year old 77,539 63.2 
Severe LRTI <1 year old 49,207 40.1 
ARI <5 years old (Kenya National Bureau of 
Statistics, 2010) 
1,069,735 180 
Outpatient consultations <1 year old 37,278 30.4 
Outpatient consultations <5 years old (Kenya 
MoPHS, n.d.); (Kenya National Bureau of 
Statistics, 2010) 
101,460; 597,982 17.1; 101 
Hospitalizations <1 year old 9,311 7.6 
Hospitalizations <5 years old 10,162 1.7 
Hospital mortality <5 years old 224 0.04 
Total mortality  
< 1 year old ; <5 years old 
2,138; 2,376 1.8; 0.4 
Notes: CYO   child-years of observation 
 
RSV associated LRTI among infants 
 
The national rate of RSV associated LRTI in infants is 63 per 1000 child-years of observation 
(CYO) for a total of 77,539 cases annually in children aged less than 1 year old. The region with 
the highest rate is the Coast with 104 cases per 1000 CYO (one infant in 10), followed by 
Nyanza with 66 per 1000 CYO, and finally Rift Valley with 65 per 1000 CYO (see appendix 6). 
However, the region which is the most affected in terms of annual number of cases is the Rift 
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Valley with a total of 22,171 cases, followed by Nyanza with 13,093 cases and the Coast with 
12,008 cases.  
 
In terms of severe LRTI cases, the national rate is 40 /1000 CYO, causing a total of 49,207 cases 
among infants. The Coast with the highest rate of 66 cases per 1000 CYO is followed by Nyanza 
which has a rate of 42 cases per 1000 CYO and the Rift Valley with 41 cases per 1000 CYO. 
The regions with the highest toll are again Rift Valley with 14,070 cases, Nyanza with 8,309 
cases and Coast with 7,621 cases among infants each year.  Rift Valley, Nyanza and Coast 
regions respectively account for 29%, 17% and 16% of the national total of RSV associated 
LRTI cases.  
 
RSV associated ARI among children under 5 years old 
 
The national annual incidence of RSV associated ARI obtained from KDHS prevalence is 
1,069,735 among children less than 5, for a rate of 180 per 1000 CYO (see column Annual 
incidence of RSV associated ARI in Appendix Table 5).  The Coast has a rate of 296 cases per 
1000 CYO, is followed by Nyanza which has a rate of 187 cases per 1000 CYO and the Rift 
Valley with 185 cases per 1000 CYO. The regions with the most cases are the Rift Valley with 
300,515 cases, Nyanza with 177,456 cases and Coast with 159,291 cases among infants each 
year.   
 
Outpatient consultations among infants 
 
The rate of outpatient consultations for infants in Kenya is 30 per 1000 CYO for a total of 37,278 
consultations of infants per year. If we consider all cases consulting are severe, it means only 
about 76 % of the 49,207 severe cases among infants seek medical care (see Appendix Table 6). 
 
The Coast is again the region with the highest rate of outpatient consultations for infants with 50 
consultations per 1000 CYO.  The Rift Valley comes in second rank and Nyanza in third rank; 
with respectively 32 and 31 infant consultations per CYO. This translates into 10,659 
consultations per year in the Rift Valley, 6,295 in Nyanza and 5773 on the Coast.  
 
Outpatient consultations among children aged less than 5 years old 
 
The number of outpatient visits of children less than 5 which would be RSV associated using the 
prevalence of 15% of all pneumonia cases recorded in HIS is about 101,460 cases, for an annual 
incidence rate of 17 per 1000 CYO (see column Annual incidence of RSV associated pneumonia 
recorded in HIS in Appendix Table 5).  
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In HIS, the Rift Valley province has the highest number of outpatient consultations with a total 
of 22,899. It is followed by the Western and the Eastern provinces with respectively 18,248 and 
15,497 outpatients consultations.  The incidence rates are 24 per 1000 CYO for the Western 
province, followed by the Coast region with 22 per 1000 CYO and the Central province with 20 
per 1000 CYO.   
 
On the other hand, according to KDHS proportion of children sick seeking health care, there 
would be 597,982 cases of RSV associated pneumonia throughout Kenya, for an incidence rate 
of 101/1000 CYO (see column Annual incidence of RSV associated ARI seeking advice in 
Appendix Table 5).  
 
When the HIS estimate is put in relation with the 37,278 outpatient consultations of infants 
estimated previously using KDHS data,  it would mean only about 37% of these consultations for 
children aged less than 5 years old would be for infants. This proportion is still much lower when 
the KDHS estimate for the consultations of children aged less than 5 years old (same estimation 
method) is used as the denominator (6%). This is not consistent with the epidemiology of RSV 
associated pneumonia, which is usually more severe in infants. Reasons for that might be that 
KDHS data collection occurred during the ARI seasonal increase as well as the conversion from 
2 week-prevalence to annual incidence both leading to overestimation. There may be over 
reporting still in KDHS due to desirability bias possible in declaring seeking health care when it 
was not, but this bias should have been consistent in the two age groups.  The HIS data might not 
be exhaustive causing underestimation in the under 5 years old consultations rate, however this 
would lead to an even smaller proportion of infants’ consultations. 
 
The infants’ rate of consultations seems more reliable as it is based on an incidence rate, but the 
regional likelihood ratios might not be adequate leading to a poor national estimate. The 
likelihood ratios were based on children aged less than 5 data for both age groups. If likelihood 
ratios would have been calculated using HIS data, the proportion of infants consulting among the 
less than 5 years old would have been lower still. It may also be possible that most the less than 1 
year old constitute a weak proportion of consultations, but account for a majority of 
hospitalizations. Given these estimates were obtained using different methods, they are hardly 
comparable. However, their comparison may provide insight into the weaknesses of the 
estimation methods.  See the Possible biases section below for further discussion. 
 
Hospitalizations among infants and children aged less than 5 years old 
The national rate of hospitalizations is 8 per 1000 CYO for infants, resulting in 9,311 
hospitalizations in 2009. This rate is of 2 per 1000 CYO for children aged less than 5 years old 
for a total of 10,162 hospitalizations in 2009. The rate of hospitalizations of infants is thus about 
4 times greater that of the 0-4 years old age group. Infant hospitalizations thus constitute 91.3% 
of the under 5 years old hospitalizations.  
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The Coast has a rate of 13 infant hospitalizations per 1000 CYO, followed by the Rift Valley and 
Nyanza with both about 8 hospitalizations per 1000 CYO. Due to its large population, the Rift 
Valley experiences 2,850 hospitalizations of infants annually, while Nyanza and the Coast region 
have about 1500 each.  
As for the children under 5 years old, the incidence is 3 hospitalizations per 1000 CYO on the 
Coast, followed by the Rift Valley and Nyanza which have rates of about 2 hospitalizations per 
1000 CYO each. This results into over 3000 hospitalizations in Rift Valley, 1,699 in Nyanza and 
1,576 on the Coast.  
Among infants, considering all hospitalized cases are severe cases, the incidence of 9,311 
hospitalizations out of the 49,207 severe LRTI cases means that only 20% of all infants with 
RSV associated severe LRTI are being hospitalized while WHO recommends hospitalization for 
all such cases (Nokes et al., 2009). It is not possible to estimate this proportion among children 
aged less than 5 years old because the incidence of ARI in that age group obtained using KDHS 
self-reported data appears overestimated.  However the fact many cases deserving to be admitted 
are not is probably due to access issues. Nokes et al. (Nokes et al., 2009) found that incidence 
estimates of hospital admissions are influenced by distance decay ie further away from the 
hospital then the lower the estimated incidence. In Nokes et al. study (Nokes et al., 2009), 92% 
of all hospital admissions of patients with RSV-associated pneumonia occurred during an 
epidemic period.  
RSV Mortality among hospitalized children under 5 years old 
The RSV associated mortality in hospitalized cases found in Nokes et al. was 2.2% in children 
aged less than 5 years old (Nokes et al., 2009). When applied to the number of hospitalizations in 
that age-group, it means there is a total of 224 deaths associated with RSV annually in the 
country (see column Mortality hospitalized cases in Appendix Table 6). The regions 
experiencing the most deaths are the Rift Valley with 67 deaths annually, 37 in Nyanza and 35 
on the Coast; respectively 30%, 17% and 16% of the national total.  
The hospital surveillance study by Nokes et al. (Nokes et al., 2009) found that the risks of very 
severe conditions, risk factors, and concurrent illness were significantly higher among RSV-
negative patients. This is consistent with a case fatality rate of 4.7% for RSV-negative patients 
versus 2.2% for RSV-positive ones. However, there is a concern for a bias in sampling of less 
severe cases as 18% of eligible children were not tested, and the case fatality among the enrolled 
patients was less than one-half that observed among all eligible children (4.4% vs 9.9%). 
Therefore, it is possible that the true case fatality rate associated with RSV is significantly higher 
than that observed, and consideration should be given to collecting a specimen post-mortem to 
address this unknown factor.   
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The other problem of extrapolating mortality rates from a research hospital setting to all hospitals 
is that most of other hospitals will be less resourced and thus mortality may well be higher in 
non-research settings. On the other hand, cases seen in research hospitals and higher level 
hospitals, better resourced, are generally more serious and at higher risk of dying. 
 
 
Total mortality among infants and children under 5 years old 
According to a case-control study which documented places of death of children under 5 years of 
age in the Gambia, only about one-third die in a hospital while 9% die in a health center and over 
half die at home (Rutherford et al., 2009). Thus from the 224 hospital deaths we would expect a 
total mortality of 672 among children aged less than 5 years old. 
 
In the KDHS household survey, the under 5 mortality in Kenya was 74 per 1,000 live births in 
2009, of which 52 (70%) occur in the first year of life (Kenya National Bureau of Statistics, 
2010). This is equivalent respectively to 1,566 and 5,485 deaths per 100,000 children per year.  
From a study in rural western Kenya, it was determined through verbal autopsies that 16.8 % of  
2954 children under 5 died of pneumonia, while this proportion increases to 20.9% when only 
children aged less than one year old are considered (n=1460) (Ombok et al., 2010). Pneumonia 
was the second cause of mortality after malaria. This means the annual pneumonia mortality rate 
in children aged less than 5 years old is 263 per 100,000 children while it is 1,146 per 100,000 
infants. 
When the RSV prevalence of 15.3% is applied, this means RSV was responsible for an estimated 
40 deaths per 100,000 children aged less than 5 years old per year and 175 deaths per 100,000 
children aged less than 1 year old per year.  RSV would thus cause 2,376 deaths among children 
aged less than 5 years old, including 2,138 deaths among children aged less than 1 year old 
(90%) in Kenya in 2009 which is far in excess of the 672 cases we would expect if only 1/3 of  
deaths occur in hospitals as mentioned previously (3x 224 deaths occurring in hospital calculated 
previously).   
This rate may be overestimated as the prevalence of RSV is probably lower in children who die 
than in those who are only sick as mentioned previously. In Nair et al., between 3 and 9% of 
acute lower respiratory infections deaths were RSV associated worldwide (Harish Nair et al., 
2010). 
In summary, according to the estimates presented here, RSV is expected to result annually in 
77,539 cases of LRTI, 49,207 cases of severe LRTI, 37,278 outpatients visits and 9,311 
hospitalizations among infants, as well as 10,162 hospitalizations and 2,376 deaths in children 
less than 5. These numbers are lower than those previously presented by Nokes et al. (Nokes et 
al., 2008) of 135,000 cases of LRTI, 85,000 cases of severe LRTI, and 17,000 hospitalizations of 
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infants. This difference is largely explained by the fact the Coast has double the prevalence 
reported in other regions in KDHS which had a great impact on likelihood ratios and thus 
provincial estimates.  
The estimates done directly from HIS and KDHS, namely the RSV associated pneumonia and 
the outpatient visits incidences among the children aged less than 5 years old, are not discussed 
further as the confidence in these estimates is limited (see possible biases section below). The 
mortality estimates are also of limited confidence because of all the potential biases discussed 
previously, they should be interpreted with much caution. 
 
Possible biases 
The incidences calculated directly from KDHS data might be overestimated because part of the 
data collection took place during the seasonal ARI increase (13 November 2008 to late February 
2009), the prevalence was self-reported (e.g. mothers overestimating the gravity of their child’s 
condition, desirability bias in reporting having sought health care) and the 2-week prevalence 
was converted into an annual incidence.  
 
KDHS was preferred over HIS to estimate the likelihood ratios because HIS thoroughness 
appears uncertain. The fact KDHS might be overestimated would not affect the ratios obtained. 
In HIS, the rate for the Coast is not the highest of the country while it is the case in KDHS. The 
Coast rate also differs less from that of the other regions. Thus lower estimates would have been 
obtained if HIS had been used for the calculation of the likelihood ratios.  KDHS was further 
based on a limited sample especially for the percentage of those who sought advice (see notes in 
appendix 6).  
 
The use of the RSV prevalence of 15.3% to estimate the number of pneumonia deaths associated 
with RSV is debatable because RSV prevalence may vary according to the health outcome 
considered as illustrated by Nokes et al. results and discussed previously (Nokes et al., 2008). It 
is usually thought to be less, however we cannot be certain in the absence of post-mortem 
assessment. 
 
 
 
Comparison with rotavirus burden 
The 10,162 hospitalizations resulting from RSV among children under 5 years old are more than 
the 8781 hospitalizations due to rotavirus according to Tate et al. (Tate et al., 2009).  However, 
with its 2,138 deaths in total, RSV would cause the equivalent of about only half (53%) of the 
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4471 deaths resulting from rotavirus estimated by Tate et al. among children aged less than 5 
years (Tate et al., 2009). The mortality rate of 40 per 100,000 children per year for the children 
under 5 years old is about two-thirds of the mortality rate of 68 per 100,000 per year for the 
children under 5 years old attributable to rotavirus (Tate et al., 2009). 
 
Concurrent illnesses 
 
In a longitudinal study of RSV hospital admissions in Kilifi, concurrent malaria parasitemia, 
severe malnutrition, and bacteremia were all significantly less common among RSV-positive 
children with pneumonia. Furthermore, a history of premature birth among infants and a 
discharge diagnosis including heart disease were marginally less frequent among RSV-positive 
children (Nokes et al., 2009).  
 
The incidence of hospitalization for RSV-LRTI was 2.5-fold (95% CI 2.04–3.03) greater in HIV 
infected children than in non-infected children in South Africa (Madhi et al., 2006).  In rural 
Mozambique, this incidence was also 2.2 to 6.5 times higher in HIV infected children under 5 
years old than in non-infected children of the same age group (O’Callaghan-Gordo et al., 2011). 
 
However, these co-morbidities might make patients at increased risk of complication and death 
before an RSV investigation can be performed, as mentioned previously.  
 
 
Economic burden 
 
Costs were estimated for the outpatient visits of infants and hospital admissions of children less 
than 5 years of age. Costs were based on WHO Choosing Interventions that are Cost Effective 
(WHO-CHOICE) and Ayieko et al. estimates (Ayieko, Akumu, Griffiths, & English, 2009; 
World Health Organization, n.d.).  In Ayieko et al. (Ayieko et al., 2009)2, cost estimations to 
health care system and caretakers were available specific for pneumonia diagnosis and by level 
of governmental hospitals. Outpatient visit cost estimates were taken from CHOICE. The cost of 
medication, investigation, transportation and loss of income3 not being available from that 
reference, those costs in district hospitals from Ayieko et al. (Ayieko et al., 2009) were applied. 
This might have caused a certain overestimation. For hospitalizations however, the conservative 
costs applicable for district hospitals were used. Costs were adjusted to 2011 inflation using the 
Consumer Price Index of Kenya (Kenya National Bureau of Statistics, 2011). Unit costs were 
                                                          
2 Estimates based on the treatment cost of 205 pneumonia cases in 7 hospitals throughout the country. 
3 Ayieko et al. reported caretakers spent an average of 1 hour and 49 min travelling to seek health care services for. 
Consequently, an average round trip would last 3 hours and 38 min, or approximately 0.5 working days. 
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estimated in 2011 US$. The 2011 exchange rate of 86.655 Kenyan shillings to the US$ was used 
(OANDA, 2011).  Those estimated costs are detailed in Appendix Table 7. 
 
Cost to governmental health care system 
 
Only costs of consultations in governmental institutions were included. The proportion of 
patients in governmental institutions were based on the observed health care seeking behaviour 
for children under 5 as recorded in the 2007 Household Health Expenditure and Utilisation 
Survey; which is a cluster randomized household survey among 8,453 households from all 
regions of Kenya (Ministry of Medical Services and Public Health, 2009). The unit cost for an 
outpatient visit was US$32.82 (2,844 KSh) and hospitalisation was US$98.39 (8,526 KSh). 
Because 64.6% of outpatients and 76.2 % of hospitalizations were done in governmental 
institutions, the total cost in health care attributable to RSV for the Kenyan government is US$ 
2,912,676 (252,398,234 KSh) (see Appendix Table 7).     
 
Societal costs  
 
The costs to caretaker include transportation and lost income. Pre-admission user fee and pre-
admission cost is added for hospitalizations. The total is US$15.89 (1,377 KSh) for an outpatient 
visit and US $40.74 (3,531 KSh) for a visit to the hospital. All patients considered this represents 
a cost of US$ 2,026,225 (175,582,763 KSh) to the Kenyan society. Despite the free health care 
services to all children under 5 years in government institutions policy in Kenya, user fees are 
still charged in district hospitals and those can be significant to caretakers (Barasa, Ayieko, 
English, & Cleary, n.d.). 
 
When Ayieko et al. used WHO CHOICE estimates to determine treatment costs, those were 
between 25% to 47% lower for pneumonia across the seven hospitals. However, Ayieko et al. 
estimates were preferred over CHOICE as they are mainly based on field data and are specific 
for pneumonia ; thus appear closer to reality. For example, the authors found that over half the 
children with pneumonia as a stand-alone diagnosis received at least 4 drugs when national 
treatment guidelines for severe pneumonia recommend that inpatients be treated with a single 
antibiotic only and those with very severe disease receive a combination of two antibiotics. This 
lack of adherence to clinical guidelines prevents rational resource use and increases costs of 
treatment. Further, while the mean cost for essential drugs in their sample would be US$ 0.36 for 
severe pneumonia and US$ 0.9 in a case of very severe pneumonia, the mean cost of a drug 
prescription for a child with pneumonia across the hospitals was between US$ 3.0 – US$ 31.2.   
 
Comparison with rotavirus burden 
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Thus, the total health care costs associated with RSV in Kenya are US$ 4,938,901. These costs 
do not take into consideration costs for episodes occurring in the community and loss of 
productivity from the caretakers even when they do not seek formal medical advice. They equate 
to about half the US $10.8 millions associated to rotavirus estimated by Tate et al. (Tate et al., 
2009). 
 
 
Prevention strategies and vaccines 
The virus spreads via large respiratory droplets from contaminated nasal secretions, so close 
contact with an infected individual or contaminated surface is required for transmission. 
However, RSV can persist for several hours on toys or other objects, which explains the high rate 
of nosocomial RSV infections, particularly in pediatric wards (Girard, Cherian, Pervikov, & 
Kieny, 2005). Frequent and careful hand washing might reduce transmission (Schickli et al., 
2009). However, the virus being so transmissible, vaccines might be the best option to control 
the disease.  
 
 
Vaccines 
Some vaccines for passive immunization such as motavizumab and palivizumab already exist. 
They are used as monoclonal antibodies for prophylaxis and treatment. However, due to their 
high cost, vast use is not possible in developing countries. Discussions will thus focus mainly on 
active immunization. Such vaccines are under development; however no vaccine is currently 
available. Due to the low mortality and wide uncertainty in its estimation, but severe morbidity 
from primary infection in early life and significant disease following re-infection in the elderly, 
the rationale for an RSV vaccine is mainly on the basis of prevention of morbidity rather than 
mortality.  
 
Challenges to the development of a safe effective vaccine 
RSV-specific antibodies are transmitted from the mother to the child through transudation of the 
placental barrier and breast milk (P. L. Collins & Murphy, 2006). They mainly protect the 
children’s lower respiratory tract (P. L. Collins & Murphy, 2006).  Their half-life is 3 weeks and 
as their quantity decreases, the children susceptibility to RSV increases (P. Collins et al., 1996). 
As mentioned previously, the first infection is generally the most serious, especially at a young 
age. The peak incidence of serious RSV thus occurs between the ages of 2 and 4 months (P. L. 
Collins & Murphy, 2006). A pediatric RSV vaccine must thus ideally be capable of stimulating 
effective resistance before the second month of life (P. Collins et al., 1996). The 
immunosuppressive effects of maternally derived serum RSV-neutralizing antibodies, as well as 
the children’s immunologic immaturity both pose challenge to the development of an efficacious 
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vaccine for that population (Schickli et al., 2009). Moreover, even natural infection does not 
trigger lasting immunity, so booster immunization might be required. Further, much care must be 
taken into the development of the vaccine to avoid disease enhancement as it was experienced 
with a formalin-inactivated vaccine candidate in the mid-1960s, impediment to breastfeeding 
which would be unacceptable in that age group, interference with other vaccines given at that age 
or any other serious side effect. 
 
Intranasal vaccines 
Intranasal vaccines offer many advantages for RSV immunization of young infants. First, they 
provide direct stimulation of the respiratory tract, RSV’s infection site, which may be critical for 
the development of long-term memory at the site of infection through homing of effector cells to 
the site of immunisation (van Drunen Littel-van den Hurk, Mapletoft, Arsic, & Kovacs-Nolan, 
2007). In addition to cell-mediated immunity, mucosal infection induces systemic immunity as 
secretory immunoglobulin A antibodies are normally synthesized, thus providing a strong first 
line of defense against invasion of deeper tissues (van Ginkel, Nguyen, & McGhee, 2000).  
Second, the route of vaccine administration has been found to play a significant role in both 
avoiding enhanced disease by immunization. Immunity resulting from intranasal inoculation 
appears to be less Th2 biased than that acquired through parenteral delivery (van Drunen Littel-
van den Hurk et al., 2007). 
 
Furthermore, intranasal administration avoids interference with maternal antibodies since the 
concentrations of maternal antibodies that reach mucosal surfaces are significantly lower than 
levels in serum (van Drunen Littel-van den Hurk et al., 2007). While a live vaccine administered 
parenterally was neutralized by maternal antibodies, an intranasal vaccine could replicate in 
upper respiratory tract (van Drunen Littel-van den Hurk et al., 2007). Maternal antibodies partly 
suppress the immune response to infection, primarily through the humoral rather than cell-
mediated immunity (P. L. Collins & Murphy, 2006).  
Finally, mucosal delivery of vaccines is non-invasive, easy to administer, and avoids the use of 
needles, which facilitates compliance and is more practical in developing countries setting (van 
Drunen Littel-van den Hurk et al., 2007). 
However, because the site of inoculation, replication and subsequent inflammation is in the 
respiratory tree, intranasal vaccines must not impede breathing and feeding in infants, the 
targeted group (Schickli et al., 2009).   
 
Alternative immunization strategies 
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As it has proven difficult to develop a safe vaccine for that age group, alternative immunizations 
strategies have been put forward.  
Cocoon-type strategy  
The cocoon strategy consists of immunization of parents and siblings to protect the infants. It 
may be an interesting approach in developing countries where infants’ main contacts are his 
family versus children in developed countries who are placed in nurseries.  
Because even natural infection does not confer complete nor lasting immunity, benefits of 
immunization will probably be partial and of limited duration. Still it would diminish the risk of 
reinfection and thus reduce the likelihood contacts will infect an infant. Repeated immunization 
would be required, on a yearly basis before epidemics, making cost-effectiveness of this strategy 
difficult to attain. However, a single immunization boost to protect the most at-risk period, 
namely the epidemic occurring during the first year of life, might suffice to limit consequences.  
Secondly, Crowcroft et al. found that in over 60% of the infants’ admitted to hospital intensive 
care units families, the infant was the primary or co-primary case (Crowcroft et al., 2008). This 
suggests that a vaccine targeted to household members will not prevent a majority of RSV 
infections to naïve infants, but the fact households were visited retrospectively might have biased 
the study. However, this observation may not apply to settings in the developing work where the 
pattern of who acquires infection from whom may well be different to the United Kingdom 
setting. 
 
Vaccine in pregnant mothers  
Theoretically, boosting the level of maternal RSV IgG should result in transfer of maternal 
antibodies across the placental barrier and in the breast milk, enhancing short-term 
immunoprophylaxis against RSV in young infants (Schickli et al., 2009). Thus, maternal 
vaccination could serve to protect very young children.  
 
Vaccination of older children 
 
A delay in vaccination, to an age when children are more immunologically mature, interference 
from maternal antibodies is avoided and safety concerns are decreased might constitute an 
effective immunization strategy.  
Although the estimated incidence of RSV-associated LRTI, severe LRTI, and hospitalization 
was highest in the group aged <6 months, significant disease incidence was observed in older 
groups continuing into the third year of life. In fact, 55%–65% of significant disease due to RSV 
in the wider community would occur in ages outside the age range typically designated as the 
vaccine target (Nokes et al., 2009).   
 
20 
 
This approach could be combined with vaccination of pregnant women to extend the period of 
protection from birth.  
 
Furthermore, if there is an effect of vaccination of elder children on the overall spread of virus in 
the population, this would provide indirect protection to the infant. 
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Vaccines currently under development 
 
The only pediatric prophylactic RSV vaccines currently under clinical evaluation are live 
intranasal vaccines based on i) attenuated RSV (rA2cp 248/404/1030∆SH or MEDI-559) or ii) 
attenuated PIV3 expressing the RSV F protein as a bivalent RSV/HPIV3 vaccine (b/hPIV3/RSV 
F2 or MEDI-534). Both are being developed by MedImmune.  
Another vaccine targeted at mothers to temporarily boost young infants’ immunity was also 
under development. It is a subunit vaccine, called RSV purified F protein (PFP)-2.  
A summary table of these three vaccines is presented in Appendix Table 8.  
 
rA2cp248/404/1030∆SH 
rA2cp248/404/1030∆SH is a cold-passaged, genetically engineered by reverse genetics live 
attenuated RSV vaccine. Its predecessor, cpts248/404, was the first live attenuated RSV vaccine 
candidate evaluated in the target population of infants as young as one month old. However, the 
vaccine caused significant nasal congestion that interfered with feeding and sleeping, which was 
inacceptable (Wright et al., 2000). The mutation of nucleotide 1030 appears to have successfully 
attenuated the vaccine while retaining immunogenicity in the rA2cp248/404/1030∆SH version. 
In a previous study, only 44% of infants who received two 105.3-pfu doses of rA2cp 
248/404/1030∆SH vaccine had detectable antibody responses (Karron et al., 2005). However, 
even though a neutralizing antibody response could not be detected in young infants (1-3 months 
old) infected with the RSV vaccine, the vaccinees had diminished virus shedding after receipt of 
a second dose, indicating that an immune response capable of restricting RSV replication had 
occurred (Karron, 2011). This surrogate for vaccine efficacy was further supported in Wright et 
al. (Wright et al., 2007) study in which the frequency of total respiratory illness and RSV-
associated upper respiratory illness was compared between vaccinees of live attenuated virus 
vaccines all derived from RSV A2 including cpts248/404 and rA2cp 248/404/1030∆SH and 
controls in the RSV season following vaccination. Both symptoms were more frequently 
observed in controls than in RSV vaccinees, suggesting that receipt of a RSV vaccine had 
decreased replication of wild type RSV sufficiently to modify illness. Indeed, the rate of RSV 
associated upper respiratory tract illness in the 388 children was 14% in RSV vaccinated children 
versus 20% in controls in the 6–24 month old group and 16% versus 25% in infants. This trend 
of decreasing RSV-associated illness in vaccine recipients during the subsequent RSV season is 
suggestive of vaccine efficacy, but authors recognized this conclusion would be premature since 
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the studies involved multiple vaccines over multiple years and were not designed to evaluate 
efficacy (Wright et al., 2007). This finding may not be confirmed when rA2cp 248/404/1030∆SH 
will be examined on its own. 
 
Further, live attenuated vaccines may potentially revert to wild type virus (van Drunen Littel-van 
den Hurk et al., 2007). Sequence analysis performed on 9 viruses recovered from 5 recipients 
revealed that in 5 instances, single nucleotide substitutions were observed at either the 248 or 
1030 codons, with reversion to the wild type coding assignment. A sixth isolate had a mixed 
population of nucleotides at the 1030 codon. Each isolate had nucleotide substitutions at no more 
than 1 codon. The 5 cp mutations, the 404 mutation, and the DSH mutation were present in all 
isolates tested, demonstrating the stability of these mutations after replication in RSV-naive 
children (Karron et al., 2005).  
 
However, according to a recent publication, infection with a series of live attenuated RSV 
vaccines, including rA2cp 248/404/1030∆SH, did not lead to enhancement of disease upon 
infection with wild type RSV in children between 1 and 24 months old (Wright et al., 2007). 
A phase 1/2a, randomized, double-blind, placebo-controlled study to evaluate the safety, 
tolerability, immunogenicity, and viral shedding of MEDI-559, a live attenuated intranasal 
vaccine against RSV in healthy 1 to <24 month-old children is currently undergoing. The study 
comprises 2 cohorts with each a treatment arm and a placebo arm of 80 children in each. The 
first cohort includes RSV seronegative children between the ages of 5 to <24 months, while the 
second cohort is of infants between 1 to <3 months of age regardless of their baseline serostatus. 
Doses of vaccines or placebo were administered at 0, 2, and 4 months. The primary outcome 
measure was the incidence of solicited adverse events from administration of study vaccine 
through 28 days following each dose, considered a safety issue. The secondary outcome measure 
is the incidence and magnitude of MEDI-559 shedding at days 7, 12, and 28 after each dose. The 
study started in October 2008. The final data collection date for primary outcome measure was 
planned for May 2011. The study should be completed by January 2012 (United States National 
Institutes of Health, 2011). 
To date, rA2cp 248/404/1030∆SH is the only attenuated RSV strain with a demonstrated safety 
profile in infants suitable for further study. Whether the vaccine may induce immunity against 
wild type RSV remains to be verified (Wright et al., 2007). However, results are very 
encouraging and thus it appears that a pediatric live RSV vaccine candidate that is sufficiently 
attenuated, optimally immunogenic and not overly reactogenic is an achievable goal (Schickli et 
al., 2009).  
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b/hPIV3/RSVF2 
 
The second vaccine candidate is b/hPIV3/RSVF2, in which RSV F is expressed from a 
bovine/human chimeric PIV3 wherein the antigenic F and HN PIV3 genes are derived from 
human PIV3 and the internal PIV3 genes are derived from bovine PIV3 (Schickli et al., 2009). It 
is thus a replicating vectored vaccine (van Drunen Littel-van den Hurk et al., 2007). Such 
vaccines may cause disease in immunocompromised  individuals (van Drunen Littel-van den 
Hurk et al., 2007).  
A phase 1 clinical trial to assess the safety of the b/hPIV3/RSVF2 vaccine in healthy RSV 
seropositive children between 1-9 years-old was completed in May 2007. Participants are 
currently being recruited for a phase 1/2a study to evaluate the safety, tolerability, 
immunogenicity and vaccine-like viral shedding of the vaccine in healthy 6 to < 24 month-old 
seronegative children and in 2 month old RSV immunity unscreened infants.  The cohorts and 
doses received are described in the table below. Doses of vaccines or placebo were administered 
at 0, 2, and 4 months. The primary and secondary outcome measures are the same as in the 
MEDI-559 trial. The study started in October 2008. The final data collection date for primary 
outcome measure is planned for December 2011, while the study should be completed by 
January 2012 (United States National Institutes of Health, 2011).  
 
 Age, number of participants, dose 
Cohort 1- Experimental 6 to < 24 mos, N = 80, 10:5 TCID:50 
Cohort 2- Experimental 6 to < 24 mos, N = 80, 10:6 TCID:50 
Cohort 3- Experimental 2 mos, N = 40, 10:4 TCID:50 
Cohort 4- Experimental 2 mos, N = 80, 10:5 TCID:50 
Cohort 5- Experimental 2 mos, N = 80, 10:6 TCID:50 
Cohort 6- Placebo N = 40 (for Cohort 3); N = 80 (for Cohorts 1,2,4 & 5) 
 
RSV-PFP 2 vaccine 
A PFP-2 has been evaluated in 35 women in the third trimester of pregnancy (Munoz, Piedra, & 
Glezen, 2003). The vaccine was administered intramuscularly. F-specific IgA and IgG in the 
milk were higher in the F-vaccinated women. 75% vaccine recipients had a response to PFP-2 by 
Western blot and 95% had a ≥4 fold rise in IgG ELISA Ab after immunization versus none in the 
placebo group (Munoz et al., 2003). Geometric mean concentrations of IgG ELISA Ab were 4 
fold higher in infants of vaccine recipients at birth, 2 and 6 months after delivery than in infants 
of placebo recipients (P < 0.01) (Munoz et al., 2003). A little increase in neutralization Ab (0.5 
log 2) was observed in vaccine recipients and their infants, there was no increase in T-cell or 
cytokine activity and there were no differences between babies of placebo and vaccine recipients 
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in rate or severity of RSV disease during the subsequent RSV season (Munoz et al., 2003). A 
substantially more immunogenic subunit RSV vaccine is needed to further evaluate this approach 
(Schickli et al., 2009).  
Subunit vaccines, such as PFP, stimulate a bias toward a Th2 immune response, which may 
theoretically predispose RSV-naïve recipients for enhanced disease, according to animal studies 
(Schickli et al., 2009). There is further evidence in mice that the quality of the immune response 
induced in the vaccinated mothers influences the bias of the immune response of newborns once 
they get vaccinated (Blomqvist, Lövgren-Bengtsson, & Morein, 2003). If this proves to be 
applicable to RSV as well, it is important that mothers are vaccinated with a vaccine that induces 
a balanced Th1:Th2 response. This could be attained through the use of a Th1 immune response 
biased adjuvant (Schickli et al., 2009). Though administration of adjuvants may increase the 
generation of neutralizing antibodies and improve the Th1:Th2 balance of subunit vaccines, they 
would likely be too reactogenic in children and infants.  
 
Also, inherent bias of the neonatal immune system towards a Th2 immune response, which can 
often lead to a Th2-dominant memory response which persists into adulthood (van Drunen 
Littel-van den Hurk et al., 2007).  
 
Thus, subunit vaccines are usually considered more appropriate for RSV experienced 
individuals, such as mothers. In young infants, subunits vaccines are further of limited efficacy 
due to the presence of maternal antibodies unless administered through mucosal delivery (van 
Drunen Littel-van den Hurk et al., 2007). Subunit vaccines offer limited duration of immunity 
(van Drunen Littel-van den Hurk et al., 2007). The development of the PFP-2 vaccine was 
abandoned by Wyeth in 2005.  
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Perceptions of stakeholders 
 
National stakeholders 
A survey was prepared for Kenyan paediatricians. The objectives were to:  
1) understand how RSV is treated in the medical system versus other LRTIs; 
2) document the knowledge of Kenyan paediatricians on a few key epidemiological aspects of 
RSV; 
3) document the perceptions of Kenyan paediatricians regarding the burden attributable to the 
virus, immunization and clinical trial for a paediatric RSV vaccine in Kenya. 
 
The data collection was held between November 10th 2011-December 9th 2011. Kenya 
Paediatricians Association accepted to circulate the survey (see questionnaire in appendix 9) 
through email to all of its members (numbering nearly 200). A reminder was sent 3 weeks after 
the initial sent out. Unfortunately, the response rate was very low with only 10 respondents, 3 of 
which abandoned before the end of the survey. Because there were so few respondents, no cross-
analysis could be performed. However, the responses to the three open questions on 1) whether 
greater attention should be paid to RSV disease and prevention in Kenya; 2) if a vaccine to 
protect infants should be considered a priority for routine use within the country; and 3) whether 
Kenya should participate in an RSV vaccine trial all generated unanimously supportive 
responses.  
However, it is important to note this sample might not be representative of the whole Kenya 
paediatrician community as those who decided to answer the questionnaire might have had an 
interest for the disease. Most worked in a national hospital and in Nairobi. This might also 
explain why the respondents had a relatively good knowledge of the epidemiology of RSV. Most 
underestimated the mortality associated to RSV in hospitalized LRTI cases. Moreover, only two 
out of seven reported being able to recognize annual RSV epidemics.  
Respondents’ characteristics 
The median number of years of practice in peadiactrics of the respondents was 6 years (n=10, 
IQR=2), with a minimum of 2 and a maximum of 24. Out of the 8 who provided details 
regarding their current work, 7 work in the national hospital, 1 in a district hospital. Five are in 
the public sector, while 3 are in private for-profit organizations and 1 is in the private not-for-
profit sector. Seven are in Nairobi, while 1 works in the Rift Valley. 
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Medical care of LRTI 
Of 7 respondents none prescribed antibiotics for LRTI other than pneumonia. All prescribed 
antibiotics for pneumonia, severe pneumonia and very severe pneumonia. For severe and very 
severe pneumonia most would give it by intravenous means (6 and 7/7 respectively), rather than 
per os as in non-complicated pneumonia (6/7). 
Knoweldge of RSV epidemiology 
When asked whether RSV was the main cause of severe pneumonia (Q5), 4/6 rightfully 
answered it is. In Berkley et al. (Berkley et al., 2010) one year study, the authors found using 
molecular methods that the prevalence of RSV in children under 12 year-old hospitalized at 
Kilifi district hospitals for severe pneumonia was 34%. Two out of 7 identified this prevalence 
correctly and 5 did not know.  The next question (Q7) was asking what percentage of children is 
infected with RSV during their first year.  The answer is two-thirds, so respondents were 
expected to pick 60%. However, only one respondent selected this proportion, while 3 said 80% 
and 3 did not know. Four recognized the peak of hospitalization for RSV is between the ages of 
2 and 4 months (Q8). One denied and 2 did not know.  
 
All of five respondents recognized RSV infection does result in long lasting immunity (Q9). All 
of six respondents to the next question knew RSV repeatedly infects throughout life (Q10).  The 
seven respondents knew the risk of disease from RSV infection decreases with age through 
childhood. When asked whether the risk of disease from RSV infection is greatest following 
primary exposure and less in subsequent exposures, six out of seven picked the right answer that 
it is true, while one said no (Q12).  
 
Only two of the seven respondents reported being able to recognize RSV epidemics each year 
when they cause a seasonal high burden on hospital bed-space (Q13). Four of the seven 
respondents correctly picked all symptoms presented: fever, coryza, cough, expiratory wheezing, 
respiratory distress. Three others selected only four of the five symptoms. Two rightfully said 
RSV symptoms usually last between 7 to 12 days; the other five said between 5 to 10 days.  
 
All seven respondents recognized RSV is the most important cause of bronchiolitis in children 
under 1 year of age (Q16). Four responded around 4-6% of infants and young children with signs 
of bronchiolitis or pneumonia during their first RSV infection require hospitalization. Three did 
not know.  Three out of seven respondents said the mortality associated with RSV is 1%. While 
this is true in United States, Nokes et al. 2009 found a 2.2% mortality among children 
hospitalized for pneumonia in Kilifi district hospital (Q18). Four others said they did not know. 
 
Four said RSV is a major cause of morbidity in children, while 3 said it was a major cause of 
both morbidity and mortality. 
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Their opinion 
 
When asked whether greater attention should be paid to RSV disease and prevention in Kenya, 
respondents were unanimous (n=6). One mentioned for both its short term and long term 
outcomes. Another highlighted the fact RSV cases in children are under-recognized in 
comparison to bacterial pneumonias, yet RSV is a major cause of hospital visits. Prevention 
would result in reduced burden on health resources and families as well as better quality of life 
for affected children as noted by someone. The misuse of antibiotics and costs associated were 
also reported.  
To the question: “If a vaccine was available to protect infants, do you think this should be 
considered a priority for routine use within Kenya?” Four out of the six respondents said yes, 
while one said not at this time. Another said maybe. Half mentioned it should come after 
rotavirus vaccine. One specified that rotavirus morbidity and mortality appeared more important. 
One added it should come after a malaria vaccine in addition to after the rotavirus one.   
All six respondents felt Kenya should participate in vaccine trials (phase 2b or 3) for an RSV 
vaccine. Three specified it would allow to obtain good data on the effectiveness of the vaccine in 
our setup and community and thus advise rationale for future vaccination initiative. Another 
mentioned the benefits for Kenyan children.  
 
International stakeholders 
Many experts in the field of vaccine development or funding were consulted to document their 
opinion on the feasibility and desirability of an RSV vaccine. The list of people who were 
contacted at least twice each is presented in appendix. People who gave detailed responses were 
Dr Osman Mansoor, Senior Adviser EPI for Unicef (Mansoor, 2011); Professor Barney Graham 
from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases 
(Graham, 2011) and Professor Ruth Karron, Director of the Center for Immunization Research of 
the Johns Hopkins Bloomberg School of Public Health (Karron, 2011). A few others replied 
saying they did not feel comfortable answering the questions. Professor Salisbury’s opinion as 
chair of the Research and Development Working Group of the Decade of Vaccine initiative was 
documented through a keynote presentation he made at Global Vaccines 202X conference in 
2011 (Salisbury, 2011).   
According to Professor Salisbury, RSV vaccine has a low feasibility at high cost.  Dr Mansoor 
was concerned about the major immunological challenges to developing an RSV vaccine and 
that consequently the development will be driven by industrialized countries where there is 
documented and large impact on infants and young children. Dr Graham estimated it would take 
5-10 years of clinical development for each new vaccine platform.  Dr Graham said he noticed a 
heightened interest from industry for an RSV vaccine in the 2 last years. 
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Since, RSV has relatively little genetic variation the virus depends largely on immune evasion 
and modulation to successfully reinfect humans. Therefore, immunizing by an approach other 
than live virus infection has the potential to induce more durable immunity (Graham, 2011).   
 
The experts were also asked which of the following immunization strategy might be most 
effective in a developing country setting:  
 
1) the vaccination of pregnant mothers to boost newborns' immunity and thus delay the age of 
the first episode, 
2) pregnant mothers’ immunization followed by immunization of the child at an older age,  
3) immunization of siblings before epidemics(cocoon strategy),  
4) delayed immunization (at 6 months-old) to prevent future burden, 
5) other.  
 
According to Dr Karron, the approach of immunizing pregnant mothers to afford passive 
protection to young infants followed by active immunization of infants during the first 6 months 
of life seems reasonable while the cocoon would not be cost-effective due to repeated 
immunization required of parents and siblings. Dr Mansoor rather felt all of the vaccine strategy 
options need to be assessed based on population impact. However, he pointed the use of vaccine 
in older children to protect their younger sibling might be hard to ‘sell’ to parents. 
Nair et al. (H Nair et al., 2011) also evaluated the emerging interventions against RSV associated 
lower respiratory infections in children through an expert opinions survey. As for active 
immunization, there were very low levels of optimism for low product cost (i.e. cost on the 
market), affordability (i.e. affordable in the population of interest at the time of introduction) and 
low cost of development. Levels of optimism regarding the criteria of answerability (i.e. 
likelihood that the emerging intervention would become available for implementation within the 
time period specified), likelihood of efficacy, deliverability, sustainability and acceptance to end 
users for the interventions were medium. While there were high levels of optimism regarding 
impact on equity (i.e. likelihood that it would improve equity in the population of interest; that 
the global poor will have access) and acceptance to health workers.  They also examined levels 
of optimism regarding a vaccine for pregnant women. Levels of optimism for such a vaccine 
were low for low product cost, affordability, answerability and low development cost; moderate 
levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; 
and high for acceptance to end users and health workers.  
Having an effective RSV vaccine would provide a significant public health benefit. It would be 
important for the vaccine approach to not interfere with polio, measles, meningitis, Hib and 
rotavirus vaccinations. Once an RSV vaccine is available, whether it is added to EPI then 
becomes a matter of cost, how the vaccine is offered (on its own or in combination) and 
availability of funding for developing countries (Graham, 2011; Mansoor, 2011). Dr Salisbury 
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described the global burden attributable to RSV as medium-high. Dr Graham suggested that 
phase I vaccine trials are typically conducted in the country where the vaccine product was 
developed. Advancing the clinical evaluation to developing countries would depend on the 
public health importance, the interest of the host country, and the available clinical trials 
infrastructure available. Prior demonstration of safety and efficacy, and efforts to reduce cost 
would improve the cost:benefit analysis and make to product more attractive.   
Dr Mansoor felt it hard to see a place for RSV vaccine in the near future because of the 
challenges in the development of an RSV vaccine and later in making it available to developing 
countries. Yet, he thinks Unicef should be supportive of both the vaccine development and its 
testing in developing countries, because it is potentially of high impact. He specified that having 
data from developing countries will be important to plan for eventual use. 
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Conclusions & Recommendations  
 
Recent progress has been made in estimating the disease burden of RSV. However, there remain 
important gaps in our knowledge. There are insufficient long term studies and few that look at 
within country variation geographically and factors relating to this. Potential long term sequelae 
of RSV which might be a major argument in favor of vaccination must further be verified. Data 
on the economic burden and the burden among adults are scarce.  
In Kenya, RSV was estimated to result annually in 77,539 cases of LRTI, 49,207 cases of severe 
LRTI, 37,278 outpatient visits and 9,311 hospitalizations among infants, as well as 10,162 
hospitalizations and 2,376 deaths in children less than 5. The hospitalizations resulting from 
RSV among children under 5 years old are more than the 8781 hospitalizations due to rotavirus.  
However, with its 2,138 deaths in total, RSV would cause the equivalent of about only half 
(53%) the 4471 deaths resulting from rotavirus among children aged less than 5 years old. While 
it causes 47% less mortality than rotavirus, RSV results in 16% more hospitalizations than 
rotavirus.   
These estimates were done with the greatest rigor; however their level of confidence depends of 
the quality of the data they are based on, which are the data available. The results are greatly 
influenced by the likelihood ratios used to adapt the Kilifi rate in each region, consequently also 
affecting the national estimate. Though KDHS sample was small, it appeared like the most 
reliable source of information as HIS thoroughness is uncertain. However, if HIS had been used 
for the likelihood ratios, the results would have been very different, the national rate lower and 
not the same regional order. Moreover, the total deaths caused by RSV might be overestimated 
because the RSV prevalence used was that of hospitalizations for severe pneumonia. RSV is 
usually associated with low mortality and the prevalence of RSV may be lower in children dying 
of pneumonia than in those hospitalized. However, there is a possible bias in sampling of less 
severe cases, the most severe ones dying before a sample could be taken, thus leading to RSV 
mortality underestimation. Post-mortem assessments should be accomplished even though it may 
be challenging to obtain authorization from parents. And it would be important to verify whether 
RSV is responsible for greater morbidity than rotavirus as this may be another incentive towards 
RSV immunization. 
The total health care costs associated with RSV in Kenya were estimated at US$ 4.9 million. 
These costs include both costs to the government and the population. However, they do not take 
into consideration costs for episodes occurring in the community and loss of productivity from 
the caretakers when they do not seek formal medical advice. This cost still represents close to 
half of the US $10.8 million associated to rotavirus. These costs estimates appear robust though 
31 
 
regional variation could not be accounted for. They could be used to determinate the minimal 
required efficacy of a vaccine candidate to attain cost-effectiveness in an immunization program.  
 
Vaccines appear like a most promising means of control. Current progresses in the research for 
an RSV prophylactic vaccine to protect young children provide hope that such a vaccine can be 
developed. However, establishing a timeline is difficult as the candidate vaccines have to pass 
through meticulous clinical trials to ensure their security and efficacy. While developing a safe 
yet immunologic vaccine for naïve children appears challenging, vaccinating pregnant mothers 
to boost newborns' immunity and thus delay the age of the first episode appears a preferred 
option over immunization of siblings before epidemics. There was consensus among national 
and international stakeholders asked that after rotavirus and malaria vaccines, RSV vaccine 
should be the next to be made available. All stakeholders, including a representative of a funding 
agency, recognized the desirability of an RSV vaccine though it should not interfere with present 
EPI schedule.  
 
In the context that severe cases and deaths concentrate in developing countries, it is essential that 
the global poor have access to an eventual RSV vaccine. Most stakeholders asked were favorable 
of a clinical trial for an RSV vaccine in developing countries/Kenya.  The local data that could 
thus be generated would be most profitable for an eventual larger campaign. They noted much 
care should be paid to ethical considerations.  While active immunization for RSV would 
improve equity in the population of interest, the cost of the product will have a great impact on 
the potential dissemination of the vaccine. It is anticipated that the market cost will be high. 
Availability of funding will thus be key in ensuring accessibility to the RSV vaccine in 
developing countries when it becomes available. 
 
It should however be noted that the response from local authorities was very low, probably a 
symptom of numerous competing health and immunization priorities (introduction of a conjugate 
Pneumococcus vaccine in March 2011); further in the absence of an RSV vaccine contender 
while other vaccines such as for rotavirus are available. More information on the burden 
attributable to RSV within Kenya might serve to emphasize the importance of the disease. 
Countrywide prevalence estimates and denominator estimates if possible are needed, as well as 
better mortality estimates including post-mortem assessment. Morbidity attributable to RSV 
must not be neglected as there are societal costs associated, which are often ignored yet probably 
substantial.  
As noted by the stakeholders, RSV might well become the next priority after rotavirus vaccine is 
introduced and a malaria vaccine shows promise. It would be in the interest of local authorities to 
then have the most accurate field data to assess the cost-effectiveness of the new vaccine. Such 
data is not presently available and can only be collected through a large scale clinical trial to 
determinate efficacy of a safe vaccine candidate (phase 3 clinical trials) for which KEMRI has 
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the experience, namely in the field of malaria vaccine research. An information campaign among 
local stakeholders might be beneficial to inform them of the burden due to RSV and thus foster a 
more favorable climate for undertaking vaccine trials early in the development stage. It is hoped 
that the data gathered here can support this purpose. 
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APPENDIX 
1 
 
1. List of contacts 
 
 
National stakeholders: 
 
 Kenya Ministry of Public Health and Sanitation 
 
Dr Tatu Kamau - Head of Division of Vaccines and Immunization, MoPHS 
tatun@wananchi.com  
 
Dr David Mutonga - Head of Division of Disease Surveillance and Response 
davidmutonga@yahoo.com 
 
 
 Kenya Pediatricians  
 
Cecilia Keiru 
Kenya Pediatricians  Association manager 
ckeiru@kenyapaediatric.org  
 
 
International stakeholders: 
 
 World Health Organization and Unicef 
 
Dr Peter Strebel 
WHO Expanded Programme on Immunization (EPI+) 
Immunization, Vaccines and Biologicals (IVB) 
strebelp@who.int 
 
Helen Rees  
WHO Strategic Advisory Group of Experts (SAGE) 
reesh@who.int 
hrees@rhru.co.za 
 
Dr Jason Mwenda  
WHO AFRO head  
mwendaj@afro.who.int  
 
Dr Osman Mansoor 
Senior Adviser EPI (New Vaccines) 
UNICEF 
omansoor@unicef.org 
 
 
 Bill &Melinda Gates Foundation  
Dr Douglas Holtzman 
Senior program officer, Global Health ProgramDouglas.Holtzman@gatesfoundation.org 
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 Decade of Vaccines Initiative (http://www.dovcollaboration.org/) 
 
David Salisbury 
Chair of the R&D Group, Decade of Vaccines Collaboration  
David.Salisbury@dh.gsi.gov.uk 
 
Laura Moya 
R&D working group coordinator of Decade of Vaccines Collaboration Secretariat,  
laura.moya@isglobal.es 
 
 Global Alliance for Vaccines and Immunization (GAVI) 
 
Dr Orin S. Levine 
Executive Director 
GAVI's Pneumo ADIP 
olevine@jhsph.edu 
 
 Researchers 
 
Professor Barney Graham, M.D., Ph.D. 
National Institute of Allergy and Infectious Diseases 
Vaccine Research Center, Clinical Trials Core Laboratory 
bgraham@mail.nih.gov 
 
Dr T. Jacob John 
Advisor Christian Medical College Hospital 
vlr_tjjohn@sancharnet.in , tjacobjohn@yahoo.co.in 
 
referred to: 
- Eric Simoes  
eric.simoes@ucdenver.edu , Eric.Simoes@uchsc.edu,  
- Thomas Cherian 
chertiant@who.int 
 
 
Vaccine developers /manufacturers (for the vaccines under development section) 
 
MedImmune (MEDI 534 and 559) 
Elissa Malkin, MalkinE@MedImmune.com 
Filip Dubovsky, DubovskyF@MedImmune.com 
David Jones, JonesD@MedImmune.com 
 
PFP-2 
Munoz, florm@bcm.tmc.edu 
Paul Glezen, wglezen@bcm.tmc.edu 
 
NanoBio 
John F. Coffey, Jr. 
Business Development 
john.coffey@nanobio.com 
 
3 
 
Ruth Karron  
Professor, Director, Center for Immunization Research; Director, Johns Hopkins Vaccine 
Initiative 
rkarron@jhsph.edu 
 
Ursula Buchholz  
Researcher, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health 
ubuchholz@niaid.nih.gov 
 
 
 
 
2. Questions asked to vaccine stakeholders 
 
A few questions on RSV 
 
Dear, 
 
I work with Professor James Nokes at the Kenya Medical Research Institute- Wellcome-Trust (KEMRI). 
We are doing a situation analysis to examine whether the climate is favorable for an RSV vaccine trial in 
Kenya. The document will be presented to the Kenyan Public Health authorities to inform them on the 
burden associated to RSV. We would also like to document the opinions of international and national 
actors in the field of RSV on RSV prevention means and in particular vaccines. We consider you are an 
expert on vaccines and would have a few questions to ask you. We would greatly appreciate if you could 
take a few moments of your time to let us know of your opinion. In case you do not wish to answer a 
particular question or do not have an opinion on it, please simply indicate it.  
 
Do you think the development of an RSV vaccine is possible? In what time frame (in terms  
of years)? 
And what about a vaccine which would confer a long lasting immunity (many years)? 
 
Given the challenges in immunizing young infants, do you think other prevention approaches might be 
promising in a developing country setting?  
Do you think alternative immunization strategies might be effective in a developing country setting, such 
as : 
1) the vaccination of pregnant mothers to boost newborns' immunity and thus delay the age of the first 
episode,  
2) pregnant mothers’ immunization followed by immunization of the child at an older age,  
3) immunization of siblings before epidemics(cocoon strategy),  
4) delayed immunization (at 6 months-old) to prevent future burden (according to Dr Nokes researches a 
majority of the disease in the community occurs after the age 6 months-old though the peak of 
hospitalization is passed), etc.?  
 
Do you think an RSV vaccine for children is relevant in a developing country? Under what conditions? Do 
you think it should eventually be added to EPI? If you are a funding agency, do you think your agency 
would support RSV immunization? 
 
What is your opinion on a RSV vaccine trial in Kenya? 
 
Finally, regarding vaccines currently under development, it appears there were some reversions in the 
vaccine 559 (rA2cp 248/404/1030 8710;SH). What is your opinion on the stability of the vaccine? To your 
knowledge, can anything be done to stabilize it? 
 
To your knowledge, are there currently other vaccines under development (aside from pre-trial stage and 
MEDI 524 or b/hPIV3/RSV F2) for RSV in children? 
 
Please confirm whether I can quote you in the report. 
 
Thank you very much in advance for your collaboration. 
Regards, 
 
Genevieve Gravel 
KEMRI intern 
MPH Epidemiology Candidate 
University of Toronto 
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3. Literature search strategies 
 
BURDEN (Jul 15th 2011) 
 
1. Medline Ovid 
RSV (MeSH) or RSV or Respiratory syncytial virus  
AND  
Developing countries (MeSH) or GAVI 56 eligible countries 2011  
 
- Humans, from 2005=87=> 35 selected 
 
2011 56 GAVI eligible countries 
(http://www.gavialliance.org/support/who/eligible/index.php) 
 
■ Afghanistan 
■ Bangladesh  
■Benin  
■Bolivia  
■Burkina Faso  
■Burundi  
■Cambodia  
■Cameroon  
■Central African Republic  
■Chad  
■Comoros  
■Congo, Dem Republic of  
■Côte d'Ivoire  
■Djibouti  
■Eritrea  
■Ethiopia  
■Gambia  
■Ghana 
■Guinea  
■Guinea-Bissau 
■Guyana  
■Haiti  
■India  
■Kenya  
■Korea, DPR  
■Kyrgyz Republic  
■Lao PDR  
■Lesotho  
■Liberia  
■Madagascar  
■Malawi  
■Mali  
■Mauritania  
■Mozambique  
■Myanmar  
■Nepal  
■Nicaragua 
■Niger 
 
■Nigeria 
■Pakistan  
■Papua New Guinea  
■Rwanda  
■São Tomé e Príncipe  
■Senegal  
■Sierra Leone  
■Solomon Islands  
■Somalia  
■Sudan  
■Tajikistan  
■Tanzania  
■Togo  
■Uganda  
■Uzbekistan  
■Viet Nam  
■Yemen  
■Zambia  
■Zimbabwe  
 
2. African Index Medicus, keywords: syncytial or RSV = 1not relevant 
 
3. Africa Journals Online, keywords: syncytial or RSV= 1 
 
4. Literature provided by Dr James Nokes, hand-picked 
 
5. List of references of the articles. 
 
2 
 
  
VACCINE (June 8th 2011) 
1. Medline Ovid 
 with keywords (RSV OR syncytial) AND (vaccine), since 2005 
1. exp Respiratory Syncytial Virus, Human/ 
2. vaccine*.mp. 
3. limit 2 to yr="2005" 
4. RSV.mp. [mp=protocol supplementary concept, rare disease supplementary concept, 
title, original title, abstract, name of substance word, subject heading word, unique 
identifier] 
5. limit 4 to humans 
6. syncytial.mp. [mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
7. limit 6 to humans 
8. 5 and 7 
9. 1 or 8 
10. 3 and 9 
 
2. Literature provided by Dr James Nokes, hand-picked 
 
3. List of references of the articles. 
 
4. Clinical trials website.  
 
5. Google to find for news releases and grey literature, keywords: RSV vaccine OR 
syncytial vaccine  
 
6. Contacts with developers and researchers involved for precisions.
 
 
4. Table 4: Rates of RSV associated LRTI in Kilifi District 
 
Indicator 
Rate 
/1000 
CYO 
Source of 
surveillance 
Years of 
surveillance Case definition Assay Reference 
LRTI <1 yo 104 Community 2002-05 
Acute cough or difficulty in breathing in association with 
one of the following: (1) increased respiratory rate for 
age, or (2) intercostal indrawing, or (3) inability to feed, 
reduced conscious level, or hypoxia 
IFAT 10 
Severe LRTI <1 yo 66 Community 2002-05 
Acute cough or difficulty in breathing with: intercostal 
indrawing, and/or inability to feed, reduced conscious 
level, or hypoxia. 
IFAT 10 
Outpatient visits <1 yo 50 Community 2002-05 See LRTI case definition above. IFAT 10 
Hospitalizations1 <1 yo 13 Community 2002-05 See LRTI case definition above. IFAT 10 
Hospitalizations <1 yo 11.1 Hospital 2002-07 
Severe pneumonia: history of cough or difficulty in 
breathing for <30 days, and lower chest wall indrawing. 
Very severe pneumonia: history of cough or difficulty in 
breathing for <30 days, when accompanied by any 1 of 
prostration (inability to feed or drink), coma, or hypoxia.3 
IFAT 18 
Hospitalizations <1 yo 20.4 Hospital 2007 WHO criteria for severe and very severe pneumonia.2 PCR 3 
Hospitalizations <5 yo 2.93 Hospital 2002-07 
See severe and very severe pneumonia case definitions 
from same reference above. IFAT 18 
Hospitalizations <5 yo 5.35 Hospital 2007 WHO criteria for severe and very severe pneumonia.2 PCR 3 
Mortality <5 yo 0.22 Hospital 2002-07 See severe and very severe pneumonia case definitions 
from same reference above. 
IFAT 18 
1 extrapolated from outpatient visits,26% of which are hospitalized 
2 WHO criteria- Severe pneumonia: cough or difficult breathing plus lower chest wall indrawing and no signs of very severe pneumonia; very severe pneumonia: 
cough or difficult breathing plus at least 1 of hypoxia, defined as an oxygen saturation <90% by fingertip pulse oximetry, inability to drink or breast feed, inability to 
sit, or impaired consciousness at admission, including infants < than 2 months of age. 
3 Hypoxia is defined as an oxygen saturation level (pO2) of <90% determined by finger tip Oxymeter. 
Notes:    CYO Child-years of observation 
IFAT Immunofluorescent Antibody Test 
LRTI Lower Respiratory Tract Infection 
PCR Polymerase Chain Reaction 
YO year(s) old 
 
 
 
5. Table 5: RSV associated events incidence, 2009 & 2010 - Using KDHS 2009 data and HIS 2010 data 
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Central  110,117 535,742 10,647 19.9 7.5 95,223 178 12.8 0.60 (45.2) 43,041 80 0.48 
Coast  115,466 537,719 11,764 21.9 12.5 159,291 296 21.3 1.00 56.4 89,840 167 1.00 
Eastern 160,668 809,563 15,497 19.1 6.0 115,114 142 10.2 0.48 (52.6) 60,550 75 0.45 
Nairobi 94,647 397,161 5,289 13.3 6.5 61,179 154 11.1 0.52 55.9* 34,199 86 0.52 
North Eastern  44,704 328,088 5,150 15.7 6.7 52,094 159 11.4 0.54 (60.9) 31,725 97 0.58 
Nyanza  199,203 947,849 11,965 12.6 7.9 177,456 187 13.5 0.63 54.6 96,891 102 0.61 
Rift Valley  341,645 1,625,721 22,899 14.1 7.8 300,515 185 13.3 0.62 58.0 174,298 107 0.64 
Western  155,514 757,490 18,248 24.1 6.0 107,709 142 10.2 0.48 (45.4) 48,900 65 0.39 
Kenya 1,221,937 5,939,333 101,460 17.1 7.6 1,069,735 180 12.9 0.61 55.9 597,982 101 0.60 
1 Source: Kenya Demographic Census 2009 (32) 
2 Source: Kenya MoPHS Health Information System, 2010 (34) 
3 Source: KDHS 2008-2009 (30) 
4 Estimated using KDHS data 
5 ARI: Acute Respiratory Infections. Symptoms of ARI (cough accompanied by short, rapid breathing, which was chest-related) is considered a proxy for pneumonia in 
KDHS (30). 
6 From reference 18, see table 2.  
Notes:    CYO Child-years of observation 
              LRTI Lower Respiratory Tract Infection 
              y years  
              An asterisk denotes a figure based on fewer than 25 unweighted cases which has been replaced by the national rate. 
              Numbers in parenthesis are based on 25-49 unweighted cases.  
 
 
 
6. Table 6: RSV associated events incidence, 2009 - Using adjusted Kilifi District rates 
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Central 62.4 16 6,871 39.6 25 4,361 7.4 30.0 33 3,304 6.3 160 688 1.4 710 755 17 8.9 
Coast 104.0 10 12,008 66.0 15 7,621 16.1 50.0 20 5,773 13.0 77 1,501 2.9 341 1,576 35 15.5 
Eastern 49.9 20 8,021 31.7 32 5,090 10.0 24.0 42 3,856 5.8 172 935 1.3 762 1,062 23 10.3 
Nairobi 54.1 18 5,119 34.3 29 3,248 6.8 26.0 38 2,461 6.7 149 634 1.5 662 600 13 6.6 
North Eastern 55.7 18 2,492 35.4 28 1,581 3.6 26.8 37 1,198 7.5 133 336 1.7 590 556 12 3.2 
Nyanza 65.7 15 13,093 41.7 24 8,309 17.0 31.6 32 6,295 8.0 126 1,584 1.8 558 1,699 37 16.9 
Rift Valley 64.9 15 22,171 41.2 24 14,070 30.6 31.2 32 10,659 8.3 120 2,850 1.9 532 3,057 67 28.6 
Western 49.9 20 7,763 31.7 32 4,927 8.4 24.0 42 3,732 5.0 199 781 1.1 883 858 19 10.0 
Kenya 63.2 16 77,539 40.1 25 49,207 100.0 30.4 33 37,278 7.6 132 9,311 1.7 584 10,162 224 100.0 
1 Risk ratio: ratio of the risk in the exposed divided by the risk in the unexposed. 
Notes:  CYO  Child-years of observation ;    LRTI   Lower Respiratory Tract Infection ;   YO   year(s) old 
In blue are rates taken from Nokes et al. 2008 and 2009 to which the regional likelihood ratio was applied.
 
 
7. Table 7: Cost estimates associated with RSV disease burden 
 Source Per patient  
US$ (KSH) 
Total 
US$ (KSH) 
OUTPATIENT 
Public health care 
Cost of visit  38 13.59 (1178) 64.6% of patients 
 
2,150,843  
(186,381,508) 
Investigation  39 13.72 (1189) 
Medication 39 5.50 (477) 
Total  32.82 (2844) 
Societal 
Caretaker time1 39 13.45 (1165) All caretakers 
1,612,201  
 (139,705,478) 
Transportation cost2 39 2.44 (212) 
Total  15.89 (1377) 
INPATIENT 
Public health care 
Total including hotel 
cost, medication and 
investigations, but 
excluding fees 
recovered through user 
fee3  
39 98.39 (8526) 
76.2% of patients 
 
761,833  
 (66,016,726) 
Societal 
Total cost to caretaker 
including user fee, pre-
admission cost, 
caretaker time and 
transportation 
39 40.74 (3531) 
All caretakers 
 
414,024  
 (35,877,285) 
TOTAL PUBLIC HEALTH CARE  2,912,676  
( 252,398,234) 
TOTAL SOCIETAL 2,026,225  
( 175,582,763) 
1 Estimated as 33% of the caretaker cost in public district hospitals 
2 Estimated as 6% of the caretaker cost in public district hospitals 
3 Estimated as 15% of the treatment cost 
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8. Table 8: Vaccines currently under development 
 
Vaccine Type and 
delivery 
Target 
population 
Status Objective of the trial and results 
if available 
Study 
completion 
(and primary 
completion) 
Advantages Disadvantag
es 
Developer 
and contacts 
Ref. 
rA2cp248/404/ 
1030∆SH 
(MEDI-559)  
Live 
attenuated 
vaccine, 
intranasal 
Young 
infants 
(from 2 
months) 
Phase 
1/2a 
ongoing 
To describe the 28-day post-
final dose safety and tolerability 
of three doses of MEDI-559 at 
10:5 FFU when administered to 
healthy RSV seronegative 
children 5 to <24 months of age 
and healthy infants 2 months of 
age regardless of baseline 
serostatus. 
 
Primary Outcome Measures:  
Incidence of symptoms through 
28 days following each dose  
 
Secondary Outcome Measures:  
Incidence and magnitude of 
vaccine-like viral shedding of 
MEDI-534 at days 7, 12, and 28 
after each dose  
Jan 2012 
(May 2011) 
- 
Inexpensiv
e 
- Induction 
of balanced 
immune 
responses 
- No 
needles 
needed as 
mucosal 
delivery 
- Safe in 
young RSV 
naïve 
infants 
-  Potential 
efficacy in 
infants with 
maternal 
antibodies 
- Potential 
for reversion 
to wild type 
- 
Over/under-
attenuation 
- Disease in 
immunocom
promised 
-Cold-chain 
necessary 
MedImmune 48, 49, 
51 
b/hPIV3/RSVF
2 
(MEDI-534) 
Replicating 
vectored 
vaccine, 
intranasal 
Young 
infants 
(from 2 
months) 
Phase 
1/2a 
ongoing 
To describe the safety and 
tolerability of multiple doses of 
MEDI-534 at 10:5 or 10:6 
TCID:50 in RSV and hPIV3 
seronegative children 6 to < 24 
months of age and at dosages 
of 10:4, 10:5 or 10:6 TCID:50 in 
unscreened infants 2 months of 
age. 
 
Primary Outcome Measures:  
Incidence of symptoms through 
28 days following each dose  
 
Jan 2012 
(Dec 2011) 
- 
Inexpensiv
e 
- Induction 
of balanced 
immune 
responses 
- No 
needles 
needed as 
mucosal 
delivery 
 
- Antibody 
production to 
the vector 
- Disease in 
immunocom
promised 
- Cold-chain 
necessary 
MedImmune 57 
2 
 
Secondary Outcome Measures:  
Incidence and magnitude of 
vaccine-like viral shedding of 
MEDI-534 at days 7, 12, and 28 
after each dose  
PFP-2 Subunit Pregnant 
women in 
3rd 
trimester 
Phase 
1/2a  
20 treatment/15 placebo 
Results: 
Geometric mean concentrations 
of IgG ELISA Ab were 4 fold 
higher in infants of vaccine 
recipients at birth, 2 and 6 
months after delivery than in 
infants of placebo recipients (P 
< 0.01).  
0.5 log 2 increase in 
neutralization Ab in vaccine 
recipients and infants. 
No increase in T-cell or cytokine 
activity.  
No differences between babies 
of placebo and vaccine 
recipients in rate or severity of 
RSV disease during the 
subsequent RSV season. 
Completed. - Stable 
- Induction 
of virus 
neutralizati
on 
antibodies 
- Not 
appropriate 
for young, 
naïve 
subjects 
- Potential 
for 
aggravated 
disease 
- Th2-biased 
immune 
responses 
unless 
formulated 
with Th1-
promoting 
adjuvant 
N/A, 
development 
abandonned 
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Respiratory syncytial virus: A survey of the views of Kenyan Paediatricians 
 
The objectives of the present questionnaire are to: 
4) understand how RSV is treated in the medical system versus the other LRTIs 
5) document the knowledge of Kenyan paediatricians on a few key epidemiological aspects of RSV 
6) document the perceptions of Kenyan paediatricians regarding the burden attributable to the virus, 
immunization and clinical trial for a paediatric RSV vaccine in Kenya 
 
The questionnaire is anonymous, we only ask you about some information on your practice.  
It should not take you more than 10 minutes to answer the questionnaire. We would be grateful if you 
could answer all the questions. In order to indicate your answers, you may type them, bold or highlight 
them. Please note the questionnaire is also available online at: 
https://www.surveymonkey.com/s/RSV_KEMRI 
We thank you very much in advance for your collaboration which will greatly help us to better 
understand how RSV is perceived among Kenyan paediatricians.  
Please do not hesitate to contact us for any inquiry at genevieve.gravel@utoronto.ca.  
 
Genevieve Gravel, Mwanajuma Ngama and Dr James Nokes 
KEMRI Wellcome-Trust Research Programme, Kilifi 
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IDENTIFICATION OF RESPONDENT 
1. Please state the number of years of practice you have in paediatrics: _____________  
2. Please list the institutions (individually) where you currently work, their type and specify their region:  
Name 
Di
sp
en
sa
ry
 
He
al
th
 C
en
te
r, 
m
at
er
ni
ty
, n
ur
sin
g 
ho
m
e 
Di
st
ric
t h
os
pi
ta
l 
(p
rim
ar
y)
 
Pr
ov
in
ci
al
 h
os
pi
ta
l 
(s
ec
on
da
ry
) 
Te
rt
ia
ry
 h
os
pi
ta
l 
(t
er
tia
ry
) 
Type Region 
Pu
bl
ic
 
Pr
iv
at
e 
fo
r p
ro
fit
 
Pr
iv
at
e 
no
t-
fo
r-
pr
of
it 
Ce
nt
ra
l 
Co
as
t 
Ea
st
er
n 
N
ai
ro
bi
 
N
or
th
 E
as
te
rn
 
N
ya
nz
a 
Ri
ft
 V
al
le
y 
W
es
te
rn
 
1.                 
2.                 
3.                 
4.                 
5.                 
 
SECTION 1: MEDICAL CARE OF LRTI  
3. What kinds of diagnostic tests are done and to approximately what proportions of patients with LRTI:  
Diagnostic test Approximate % of patients 
Culture from sputum  
Molecular methods  
Colour of sputum  
Chest X-ray  
Sputum Gram stain  
S.pneumoniae antigen in urine  
Rapid test (e.g. influenza)  
Biomarkers  
Other:  
 
4. Would you prescribe antibiotics in case of the following types of LRTI and if so, specify the route of 
administration: 
Types of LRTI Prescribe antibiotics  Route of administration if applicable  
(IV, PO) Yes No 
No pneumonia     
Pneumonia    
Severe pneumonia    
Very severe pneumonia    
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SECTION 2: EPIDEMIOLOGY AND BURDEN OF RSV 
5. List in order of frequency the causes of severe pneumonia among Kenyan children (1 being the most 
common, 5 the least): 
_____   Human parainfluenza virus 
_____   Pneumococcus 
_____   Respiratory syncytial virus (RSV) 
_____   Adenovirus 
_____   Haemophilus influenza type b (Hib) 
 
6. In a study of the viral etiology of severe pneumonia among Kenyan children over a full calendar year 
using molecular diagnostics, RSV was detected in about ______% of the cases (identify the answer you 
think is right, one answer). 
• 15 % 
• 25 % 
• 35 % 
• Do not know 
 
7. _____%of infants are infected (irrespective of disease outcome) with RSV during their first year of life 
(identify the answer you think is right, one answer).   
• 40% 
• 60% 
• 80% 
• Do not know 
 
8. The peak of hospitalization for RSV is between the ages of 2 and 4 months (indicate whether the 
statement is right). Yes/ No/ Do not know 
 
9. An infection with RSV result in long lasting immunity (indicate whether the statement is right). Yes/ 
No/ Do not know 
10. RSV repeatedly infects throughout life (indicate whether the statement is right).  Yes/No/Do not 
know 
11. Through childhood, the risk of disease from RSV infection decreases with age (indicate whether the 
statement is right). Yes/ No/ Do not know 
12. The risk of disease from RSV infection is greatest following primary exposure and less in subsequent 
exposures (indicate whether the statement is right).  Yes/No/Do not know 
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13. I can recognize RSV epidemics each year when they cause a seasonal high burden on hospital bed-
space (indicate whether you agree with the statement). Agree/ Disagree/ Do not know 
14. In newborns, infants and young children RSV causes upper and lower respiratory tract disease 
characterized by (identify all those that apply): fever, coryza, cough, expiratory wheezing, respiratory 
distress. Do not know. 
15. RSV symptoms usually last (identify the answer you think is right, one answer): 
• between 5 to 10 days 
• between 7 to 12 days 
• between 10 to 15 days 
• Do not know 
 
16. RSV is the most important cause of bronchiolitis in children under 1 year of age (indicate whether the 
statement is right). Yes/No/Do not know 
17. During their first RSV infection, around ____% of infants and young children with signs of 
bronchiolitis or pneumonia require hospitalization (identify the answer you think is right, one answer). 
• 1-2% 
• 3-4% 
• 4-6% 
• Do not know 
 
18. The associated mortality among hospitalized cases of children less than 5 years is around (identify 
the answer you think is right, one answer): 
• 1% 
• 2% 
• 3% 
• Do not know 
 
19. RSV is a major cause of ____________ in your children (identify the answer you think is right, one 
answer). 
• Morbidity 
• Mortality 
• Morbidity and mortality 
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SECTION 3: YOUR OPINION 
 
20. In your opinion, should greater attention be paid to RSV disease and prevention in Kenya (identify 
your answer)?  
Yes/No/ Maybe/Do not know 
Please briefly specify why? 
____________________________________________________________________________ 
 
21. If a vaccine was available to protect infants, do you think this should be considered a priority for 
routine use within Kenya (identify your answer)?  
Yes/No/ Maybe/Do not know 
Please briefly specify why? 
____________________________________________________________________________ 
 
22. Do you believe Kenya should participate in vaccine trials (phase 2b or 3) for an RSV vaccine (identify 
your answer)?  
Yes/No/ Maybe/Do not know 
Please briefly specify why? 
____________________________________________________________________________ 
 
Thank you very much! 
 
Do you have any further comments you may like to add?  
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
 
